KTTA
Pasithea Therapeutics Corp.
There isn't enough reported data to score KTTA yet.
KTTA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
KTTA's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
KTTA PE Valuation
KTTA has no meaningful PE right now: it lost money over the past year.
KTTA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect KTTA's losses to grow, with revenue declining.
KTTA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$2.05 | +$5.53 |
| Q1 2026 | -$2.55 | +$8.08 |
| Q4 2025 | -$4.04 | +$8.65 |
KTTA is still losing money, but far less than before: $2.05 per share over the past year, against $12.69 at its worst in late 2024.
KTTA Quarterly Revenue
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2022 | -2111% | N/A |
| Q3 2022 | -1944% | N/A |
| Q2 2022 | -22679% | N/A |
| Q1 2022 | -17605% | N/A |
KTTA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$4.7M | -$838.6K |
| Q1 2026 | -$4.8M | -$1.7M |
| Q4 2023 | -$3.3M | +$1.1M |
| Q3 2023 | -$3.2M | +$2.2M |
| Q2 2023 | -$3.1M | -$667.4K |
| Q1 2023 | -$3.3M | -$614.8K |
| Q4 2022 | -$4.4M | -$2.7M |
KTTA has burned cash in almost every quarter: −$18M over the past year, against −$13M the year before.
KTTA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +32% | +7.8M shares |
| 1 year | +469% | +26.5M shares |
| 3 years | +2638% | +30.9M shares |
KTTA has 32M diluted shares, up 469% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
KTTA Net Leverage
KTTA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
KTTA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.9 | Neutral |
| Stochastic | 55.2 | Neutral |
KTTA's weekly RSI is 48 (neutral) and its Stochastic is 55 (neutral).
KTTA PE vs Healthcare Sector
KTTA has no meaningful PE right now: it lost money over the past year.
KTTA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.47 | 11% above |
| 20 week MA | $0.49 | 6.1% above |
| 50 week MA | $0.69 | 25% below |
| 100 week MA | $0.94 | 45% below |
| 200 week MA | $4.18 | 88% below |
KTTA has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 88% below its 200-week average.
KTTA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $63.0 | $40.2 | -36% |
| 2022 | $40.2 | $11.6 | -71% |
| 2023 | $11.6 | $7.40 | -36% |
| 2024 | $7.40 | $2.73 | -63% |
| 2025 | $2.73 | $1.12 | -59% |
| 2026 YTD | $1.12 | $0.52 | -54% |
KTTA has finished every year since 2021 lower, and it's down 54% so far in 2026.